“It’s a good change to make, going from a country-specific operation into a more strategic role, a global role – one where you basically define and execute the strategy for the most important business we have in Sandoz for the next five to 10 years,” Peter Stenico, Sandoz’s global head for biosimilars, tells Generics Bulletin.
After three years as Sandoz’s head for Germany, Stenico took up his latest role overseeing the company’s multi-billion-dollar annual global biosimilars business on 1 January, crowning a 20-year tenure at Sandoz ahead of the company preparing to spin off from its parent Novartis before